BC
ALDR

Birchview Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

Birchview Capital’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,150
Closed -$315K – 44
2017
Q1 		$315K Hold
15,150
– – 0.18% 28
2016
Q4 		$315K Hold
15,150
– – 0.19% 26
2016
Q3 		$496K Buy
15,150
+10,000
+194% +$305K 0.29% 24
2016
Q2 		$129K Buy
+5,150
New +$139K 0.09% 42

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Birchview Capital's ALDR Position: Q2 2017 in Review

Birchview Capital sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 15,150 shares — an estimated $315K sold.

Birchview Capital first reported a position in ALDR in Q2 2016 and held it in 4 quarters. The position peaked at $496K in Q3 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Birchview Capital reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Birchview Capital sold 15,150 Alder Biopharmaceuticals shares in Q2 2017, an estimated $315K.
  • Birchview Capital first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Birchview Capital's Alder Biopharmaceuticals position peaked at $496K in Q3 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Birchview Capital's 13F filing for Q2 2017, filed 8 Aug 2017.